ePrints

Combining Genotype Profiling with MRD for More Accurate Prognostication in Acute Lymphoblastic Leukemia

Lookup NU author(s): Dr Amir EnshaeiORCiD, Professor Anthony MoormanORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

IntroductionThe assessment of treatment response by the measurement of minimal residual disease (MRD) at end of induction (EOI) is the most powerful prognostic factor in acute lymphoblastic leukemia (ALL).The integration of MRD monitoring into risk adapted protocols has been used to successfully personalize therapy intensity.^1,2However, MRD alone is not sufficient to fully predict outcome. Somatic genetic abnormalities define fundamentally distinct biological subgroups and several are important prognostic and predictive biomarkers. However, dichotomization of continuous variables leads to loss of statistical power. Current risk stratification algorithms apply risk factors independently which may wrongly assume identical associations across biologically heterogeneous subsets.

Publication metadata

Author(s): Bartram J, O'connor D, Enshaei A, Moorman A

Publication type: Article

Publication status: Published

Journal: Clinical Lymphoma, Myeloma and Leukemia

Year: 2019

Volume: 19

Issue: Supplement 1

Pages: S63-S65

Print publication date: 01/09/2019

Online publication date: 28/08/2019

Acceptance date: 02/04/2018

ISSN (print): 2152-2650

ISSN (electronic): 2152-2669

Publisher: Elsevier

URL: https://doi.org/10.1016/j.clml.2019.07.420

DOI: 10.1016/j.clml.2019.07.420

Altmetrics

Share